@article {7801,
	title = {First-line bortezomib benefits patients with multiple myeloma},
	journal = {Nature Reviews Clinical Oncology},
	volume = {6},
	year = {2009},
	note = {Cited By :5Export Date: 21 February 2017},
	month = {2009},
	pages = {683 - 685},
	abstract = {Bortezomib-based regimens are beneficial in the treatment of patients with symptomatic, newly diagnosed and relapsed or refractory multiple myeloma. researchers who investigated the efficacy and safety of single-agent bortezomib as first-line therapy in patients with myeloma have particularly emphasized the incidence and management of peripheral neuropathy, which is the most common adverse effect of bortezomib administration. {\textcopyright} 2009 Macmillan Publishers Limited. All rights reserved.},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-75649129122\&doi=10.1038\%2fnrclinonc.2009.171\&partnerID=40\&md5=22a0087777d49318958fcd1fa5ca5b3c},
	author = {Dimopoulos, M.A. and Terpos, E.}
}
